Layoffs
GlaxoSmithKline outsources diabetes researchers and fires scientists
Word on the street is that drug conglomerate GlaxoSmithKline is going to be firing up to 250 researchers and replacing them with outsourced employees from “lower-cost countries.”
An un-named GSK windbag was sympathetic enough to say this:
“There is a whole lot of reshuffling going on companywide. Unfortunately, as part of that process, jobs are going to be lost.” - Some Asshole © 2008
To add insult to injury, GSK asked all employees who were candidates for layoffs to interview for positions that would still be available after the cuts. It’s sad when your management gameplan comes straight from Office Space.
More on this topic
(What's this?)
Exanatide's convenience may not be enough in a tough Diabetes market place
(Biotechnology Stock, 6/23/08)
American Diabetes Association's 68th Scientific Sessions: A New Look at Insulin Therapy
(Pipeline Review, 6/8/08)
Oral Insulin: Balancing Safety with Efficacy
(Pipeline Review, 6/7/08)
30. September 2008 at 9:39 am :
[...] cutting 850 research and development positions “in a bid to improve productivity.” The layoffs the company had in June must have improved efficiency so much, that they felt the need to go through another [...]